H1B Salary Data

Home › Employers › EpiVax, Inc.

EpiVax, Inc.: H-1B salaries and sponsorship

EpiVax, Inc. filed 4 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $54,000.

Applications (LCAs)4
Certified3
Employer addressProvidence, RI
H-1B dependent employerNo
Median offered salary$54,000
Middle half of salaries$49,500–$62,786
10th–90th percentile$46,800–$68,058

Does EpiVax, Inc. sponsor H-1B visas?

EpiVax, Inc. filed 4 labor condition applications in fiscal years 2023–2026, the latest submitted on Jun 10, 2025. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Bioinformatics Analyst II2$71,573
Bioinformatics Analyst1$45,000
Research Scientist1$54,000

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20232$49,500
FY20252$71,573

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Bioinformatics Analyst II$71,573–$90,000
Level I
Providence, RIJun 10, 2025Oct 1, 2025Certified
Bioinformatics Analyst II$71,573–$90,000
Level I
Providence, RIJun 10, 2025Oct 1, 2025Withdrawn
Research Scientist$54,000–$84,000
Level I
Providence, RIJun 30, 2023Aug 10, 2023Certified
Bioinformatics Analyst$45,000–$90,000
Level I
Providence, RIMay 25, 2023Oct 1, 2023Certified

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).